Rahma, Osama

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Luoma, A. M., Suo, S., Williams, H. L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F. S., Rahma, O., Sullivan, R. J., et al. (2020) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 484

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón, L. J., Maurer, D. M., O’Hara, M. H., O’Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., et al. (2022) · Nature Medicine

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 384

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 307

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 218

Aging, immune senescence, and immunotherapy: a comprehensive review

Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 96